In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab and certolizumab pegol (CDP870). - Fossati,G.; Nesbit,AM.. (Am J Gastroenterol, 2005)